Mesenchymal stem cells (MSCs) have multiple functions, including tissue repair, immune regulation, promotion of angiogenesis, anti-apoptosis, antioxidant, anti-fibrosis, and homing. They hold great potential in the treatment of various diseases such as autoimmune disorders, lung diseases, and tissue injury.

MSCs derived from induced pluripotent stem cells (iPSCs) (iMSCs) have several advantages over traditional MSCs, including large batch production, consistent quality, stable efficacy, and ease of genetic modification.

Company‘s first iPSC-derived MSC cell therapy product (iMSC) has received CDE's clinical tacit approval, making it the first iMSC cell therapy product approved for clinical use in China. In the future, Nuwacell Biotechnologies Co., Ltd. will continue to develop iMSC cell therapy products for different indications.